Growth Metrics

Incyte (INCY) EBIT Margin (2010 - 2026)

Incyte posted quarterly EBIT Margin of 23.66% for Q1 2026, up 417.0% year-on-year from 4.58% in Q1 2025, and up 6.15% on a QoQ basis from 22.29% in Q4 2025.

Incyte (INCY) has 17 years of EBIT Margin data on file, last reported at 23.66% in Q1 2026.

  • For the quarter ending Q1 2026, EBIT Margin rose 417.0% year-over-year to 23.66%; the trailing twelve-month figure through Mar 2026 stood at 30.05% (up 2609.0% YoY), and the FY2025 full-year result was 29.46%, up 2802.0% from the prior year.
  • EBIT Margin for Q1 2026 stood at 23.66%, up from 22.29% in the prior quarter.
  • Across five years, EBIT Margin topped out at 43.63% in Q2 2025 and bottomed at 45.81% in Q2 2024.
  • The 5-year median for EBIT Margin is 19.49% (2025), against an average of 16.35%.
  • The widest annual swing landed in 2024, when EBIT Margin sank 6611 bps; it then surged 8944 bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 7.56% in 2022, then jumped by 144 bps to 18.48% in 2023, then soared by 38 bps to 25.58% in 2024, then fell by 13 bps to 22.29% in 2025, then climbed by 6 bps to 23.66% in 2026.
  • The last three EBIT Margin figures came in at 23.66% (Q1 2026), 22.29% (Q4 2025), and 32.47% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 38.10%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 17.83%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 23.02%
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn 23.66%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 23.66%
Dec 31, 2025 22.29%
Sep 30, 2025 32.47%
Jun 30, 2025 43.63%
Mar 31, 2025 19.49%
Dec 31, 2024 25.58%
Sep 30, 2024 12.84%
Jun 30, 2024 -45.81%
Mar 31, 2024 10.43%
Dec 31, 2023 18.48%
Sep 30, 2023 23.36%
Jun 30, 2023 20.30%
Mar 31, 2023 3.06%
Dec 31, 2022 7.56%
Sep 30, 2022 16.81%
Jun 30, 2022 27.92%
Mar 31, 2022 15.89%
Dec 31, 2021 12.83%
Sep 30, 2021 28.96%
Jun 30, 2021 19.96%
Mar 31, 2021 16.34%
Dec 31, 2020 20.80%
Sep 30, 2020 0.86%
Jun 30, 2020 33.54%
Mar 31, 2020 -116.80%
Dec 31, 2019 16.40%
Sep 30, 2019 24.35%
Jun 30, 2019 18.61%
Mar 31, 2019 14.88%
Dec 31, 2018 -4.36%
Sep 30, 2018 6.92%
Jun 30, 2018 15.96%
Mar 31, 2018 -17.56%
Dec 31, 2017 0.38%
Sep 30, 2017 3.94%
Jun 30, 2017 2.22%
Mar 31, 2017 -34.69%
Dec 31, 2016 -20.01%
Sep 30, 2016 8.27%
Jun 30, 2016 18.10%
Mar 31, 2016 13.68%
Dec 31, 2015 7.00%
Sep 30, 2015 -0.05%
Jun 30, 2015 -4.54%
Mar 31, 2015 -4.35%
Dec 31, 2014 -20.67%
Sep 30, 2014 35.30%
Jun 30, 2014 -26.30%
Mar 31, 2014 -25.54%
Dec 31, 2013 -29.91%
Sep 30, 2013 -15.49%
Jun 30, 2013 17.03%
Mar 31, 2013 -5.76%
Dec 31, 2012 11.99%
Sep 30, 2012 -16.76%
Jun 30, 2012 17.59%
Mar 31, 2012 -94.50%
Dec 31, 2011 -152.79%
Sep 30, 2011 -250.89%
Jun 30, 2011 -244.57%
Mar 31, 2011 -49.49%
Dec 31, 2010 19.93%
Sep 30, 2010 -130.73%
Jun 30, 2010 27.33%
Mar 31, 2010 -114.70%